Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Patients With Metastatic Breast Carcinoma

NCT00225056 is registered in ClinicalTrials.gov with Oncology Specialties, Alabama as lead sponsor.

NCT NCT00225056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00225056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Patients With Metastatic Breast Carcinoma
Lead sponsor
Oncology Specialties, Alabama
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2003
Completion date
November 30, 2006
Enrollment
43
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer